[Blood viscosity in patients receiving continuous treatment with bendroflumethiazide (Centyl with potassium chloride)].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to F Skovborg.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
In 10 patients with acute cardiogenic pulmonary oedema, treatment with large doses of intravenous frusemide (mean dose 156 mg) induced no signs of haemoconcentration. On the contrary, during an observation period of 2 h after start of treatment we registered a significant reduction of mean blood viscosity and mean haematocrit, indicating haemodilution. All the patients also received a basic treatment of intravenous pethidine and nasal oxygen and the conclusion is therefore that large doses of intravenous frusemide in treatment of acute cardiogenic pulmonary oedema can be given without risk of haemoconcentration when combined with intravenous pethidine and nasal oxygen.
Some workers regard whole-blood and plasma viscosity as provoking factors in Raynaud's disease. There was no significant difference, however, in whole-blood and plasma viscosity between ten young women with primary Raynaud's phenomenon and ten age and sex matched controls. Venesection, which reduces plasma viscosity, did not change the ease with which Raynaud's phenomenon was provoked in five patients. Increased viscosity might be a causal factor in secondary forms of Raynaud's disease, but it does not seem to be an important factor in primary Raynaud's disease.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.